Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atacicept (TACI-Ig), a recombinant fusion protein, comprises the extracellular, ligand-binding segment of the TACI receptor fused with the Fc portion of human IgG. It functions by inhibiting B cell activation through binding to both B lymphocyte stimulator and a proliferation-inducing ligand, and is utilized in researching B-cell autoimmune diseases [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Atacicept (TACI-Ig), a recombinant fusion protein, comprises the extracellular, ligand-binding segment of the TACI receptor fused with the Fc portion of human IgG. It functions by inhibiting B cell activation through binding to both B lymphocyte stimulator and a proliferation-inducing ligand, and is utilized in researching B-cell autoimmune diseases [1] [2]. |
In vivo | Atacicept (TACI-Ig; 100 μg; i.p.; tri-weekly for 2 weeks; BALB/c mice) decreases mature B-cell populations and serum immunoglobulin concentrations in healthy mice [1]. Additionally, it impedes disease advancement and reduces autoantibody levels in a collagen-induced arthritis (CIA) mouse model [1]. |
Synonyms | TACI-Ig, TACI-Fc 5 |
Molecular Weight | N/A |
CAS No. | 845264-92-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Atacicept 845264-92-8 TACI-Ig TACI-Fc 5 inhibitor inhibit